Mycovia Pharmaceuticals
Pharmaceuticals, 4721 Emperor BLVD, Durham, North Carolina, 27703, United States, 11-50 Employees
Phone Number: 91********
Who is MYCOVIA PHARMACEUTICALS
Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough...
Read More
- Headquarters: 4721 Emperor BLVD, Durham, North Carolina, 27703, United States
- Date Founded: 2018
- Employees: 11-50
- Revenue: $25 Million to $50 Million
- Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from MYCOVIA PHARMACEUTICALS
Mycovia Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Mycovia Pharmaceuticals
Answer: Mycovia Pharmaceuticals's headquarters are located at 4721 Emperor BLVD, Durham, North Carolina, 27703, United States
Answer: Mycovia Pharmaceuticals's phone number is 91********
Answer: Mycovia Pharmaceuticals's official website is https://mycovia.com
Answer: Mycovia Pharmaceuticals's revenue is $25 Million to $50 Million
Answer: Mycovia Pharmaceuticals's SIC: 5122
Answer: Mycovia Pharmaceuticals has 11-50 employees
Answer: Mycovia Pharmaceuticals is in Pharmaceuticals
Answer: Mycovia Pharmaceuticals contact info: Phone number: 91******** Website: https://mycovia.com
Answer: Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough therapies in womens health and dermatology. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a yeast infection that affects millions of women each year and often leads to distressing physical discomfort and a negative impact on psychological well-being. In studies to date, VT-1161 has demonstrated a high degree of potency against the organisms that cause RVVC. It may also have a lesser tendency to induce drug resistance and the variety of side effects that limit the use of currently available oral antifungal therapies. We are conducting global Phase 3 clinical trials in RVVC. VT-1161 has also been studied in onychomycosis, a fungal infection of the nail which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for diabetics or other patients with compromised immune systems or poor circulation of the lower extremities.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month